ADAR1 Capital Management »

Relmada Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Relmada Therapeutics (RLMD) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Relmada Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Relmada Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Relmada Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $243k 59k 4.14

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Royalty Pharma Shs Class A (RPRX)
Keros Therapeutics (KROS)
Roivant Sciences SHS (ROIV)
Cytokinetics Com New (CYTK)
Arbutus Biopharma (ABUS)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New (MACK)
Cerevel Therapeutics Hldng I (CERE)
Mirati Therapeutics
Merck & Co (MRK)
Ascendis Pharma A/s Sponsored Adr (ASND)
Immunovant (IMVT)
Viking Therapeutics (VKTX)
Protagonist Therapeutics (PTGX)

View all positions for ADAR1 Capital Management

Top funds holding Relmada Therapeutics

Vanguard Group
Parsons Capital Management
Opaleye Management
Palo Alto Investors
Citadel Advisors
Two Sigma Advisers
Two Sigma Investments
Point72 Asset Management
Deutsche Bank Aktiengesellschaft
Jacobs Levy Equity Management
Bank of America Corporation
Millennium Management
Guild Investment Management
Marshall Wace
Barclays

View all funds holding Relmada Therapeutics